Please ensure Javascript is enabled for purposes of website accessibility

What's MannKind Really Worth?

By Keith Speights - Sep 17, 2013 at 6:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Overpriced? Undervalued? Priced about right? A look at how much MannKind is worth.

Here's your one-question pop quiz of the day. Does MannKind (MNKD 1.97%) deserve a market cap of:

  1. $1.4 billion
  2. $1.7 billion
  3. $2.2 billion
  4. None of the above

What's the correct answer? It depends on whom you believe. Here are reasons any one of these answers could be right.

1. $1.4 billion

This is close to the market cap that Bank of America's Steve Byrne thinks MannKind is worth. He recently downgraded the stock from neutral to underperform and also lowered the price target from $8 per share to $5.

Why such pessimism? Byrne's action came after a survey of 75 doctors was conducted to determine their interest in Afrezza based upon MannKind's recently released phase 3 study results. The physicians took a more cautious stance about the inhaled insulin than in the past, leading Bank of America to presume that capturing market share could be more difficult than earlier thought.

2. $1.7 billion

Right now, the market is saying the answer is "2," give or take a little. To put that valuation in perspective, let's look at a company with a similar market cap: Nektar Therapeutics (NKTR 3.84%), which has a market cap of more than $1.5 billion. This comparison is a little ironic, because Nektar years ago failed commercially with an inhaled insulin product, Exubera, along with partner Pfizer (PFE 3.77%). That's the past, though, and there are plenty of reasons why Afrezza is superior to Exubera.

I think the mere fact that the market is placing a higher price tag on MannKind right now shows that many investors expect much more from Afrezza. MannKind has only one product, while Nektar counts 13 in clinical trials, six of which are in phase 3. MannKind doesn't yet have a revenue-generating product. Nektar does, with more than $96 million in revenue coming in over the last 12 months (although a significant portion of that revenue stemmed from collaborations with larger partners). 

There is definitely some level of optimism about Afrezza's chances already baked into MannKind's price.

3. $2.2 billion

If we look at analysts' estimates for where MannKind's value will be within a year, "3" looks to be about right. The mean one-year price target for the seven analysts surveyed by Thomson Reuters is $7.46 per share, which equates to a market cap just north of $2.2 billion.

Is this price target a stretch? Not really. MannKind traded above this level just a little over a month ago. A negative market reaction to generally positive phase 3 study results brought the stock down somewhat. It wouldn't be surprising for good news (like snagging a marquee commercialization partner or FDA approval) to lift shares to this level or even higher.

4. None of the above

MannKind bulls and bears could both easily go with this answer. The most pessimistic analyst, for example, set a price target of only $4 per share, reflecting a market cap of below $1.2 billion. The most optimistic analyst thinks MannKind will climb to $11 per share, which would put its market cap at nearly $3.3 billion.

At least one potential rival is already dismissing Afrezza to some extent. Novo Nordisk's (NVO -0.65%) CFO Jesper Brandgaard said recently that his company sees Afrezza as "solely a product you use for mealtime." Brandgaard noted that patients who use mealtime insulin often also need long-acting insulin, which would currently require an injection. Novo, by the way, also threw in the towel on its inhaled insulin product several years ago following Pfizer and Nektar's failure.

This view, though, focuses more on Afrezza's attraction as an inhaled insulin versus an injected insulin and doesn't really address what many would say is Afrezza's greatest strength: how well it works. Afrezza acts rapidly and mimics the normal functioning of a healthy pancreas relatively closely.

On the bullish side, investment firm Piper Jaffray thinks that Afrezza could hit peak annual sales of more than $2 billion, assuming approval in the U.S. and Europe. If this estimate is in the ballpark, MannKind could be worth a lot more than $2.2 billion in the future.

Best guess
To me, the safest answer for this quiz is "none of the above." I'm not sold on the idea that a survey of 75 doctors accurately represents the opinions of the the entire medical community. MannKind must get a partner to help commercialize Afrezza. If it gets a good one with a solid sales team in place for the diabetes market, my hunch is that doctors can be swayed to try Afrezza. I suspect that patients will like it if the doctors prescribe it. In this scenario, that $3.3 billion market cap from the most optimistic analyst will likely be blown away.

However, the key word in the above paragraph is "if." If MannKind doesn't land a partner with a sales team that can effectively educate physicians and if that physician survey was on target, I wouldn't be surprised to see the market cap drop even lower than $1.4 billion.

I think that MannKind will secure a solid partner, but none of us can be absolutely sure. I'm definitely not a bear on MannKind, because my view is that Afrezza holds tremendous potential. On the other hand, I'm not quite as gung ho as many of the company's most ardent supporters. Call me cautiously optimistic. My caution has overridden my optimism for now, though: I don't currently own any MannKind stock.

What do you think? Leave your thoughts in the comments section below. Anyone who makes a solid case for their answer, regardless of what it is, automatically gets an "A" on the quiz.

Fool contributor Keith Speights has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MannKind Corporation Stock Quote
MannKind Corporation
$4.15 (1.97%) $0.08
Pfizer Inc. Stock Quote
Pfizer Inc.
$50.11 (3.77%) $1.82
Novo Nordisk A/S Stock Quote
Novo Nordisk A/S
$107.50 (-0.65%) $0.71
Nektar Therapeutics Stock Quote
Nektar Therapeutics
$5.14 (3.84%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.